ES2195408T3 - Microparticulas perforadas y procedimientos de uso. - Google Patents
Microparticulas perforadas y procedimientos de uso.Info
- Publication number
- ES2195408T3 ES2195408T3 ES98953220T ES98953220T ES2195408T3 ES 2195408 T3 ES2195408 T3 ES 2195408T3 ES 98953220 T ES98953220 T ES 98953220T ES 98953220 T ES98953220 T ES 98953220T ES 2195408 T3 ES2195408 T3 ES 2195408T3
- Authority
- ES
- Spain
- Prior art keywords
- dispersions
- patient
- suspension medium
- use procedures
- microstructures
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nanotechnology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Optics & Photonics (AREA)
Abstract
Una composición en polvo que comprende una pluralidad de microestructuras perforadas, comprendiendo dichas microestructuras un ingrediente activo, un diámetro medio aerodinámico inferior a 5 ìm, y una densidad aparente inferior a 0, 5 g/cm3, en la que, cuando se suspende en un medio fluido, el volumen del medio desplazado por las microestructuras perforadas comprende menos del 70% del volumen medio de la microestructura definido por la barrera de la microestructura si las microestructuras fueran macizas.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6033797P | 1997-09-29 | 1997-09-29 | |
US60337 | 1997-09-29 | ||
US10693298A | 1998-06-29 | 1998-06-29 | |
US106932 | 1998-06-29 | ||
US13384898A | 1998-08-14 | 1998-08-14 | |
US133848 | 1998-08-14 | ||
PCT/US1998/020602 WO1999016419A1 (en) | 1997-09-29 | 1998-09-29 | Perforated microparticles and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2195408T3 true ES2195408T3 (es) | 2003-12-01 |
ES2195408T5 ES2195408T5 (es) | 2010-11-25 |
Family
ID=27369827
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES98954933T Expired - Lifetime ES2195415T3 (es) | 1997-09-29 | 1998-09-29 | Preparaciones estabilizadas para su uso en nebulizadores. |
ES98950826T Expired - Lifetime ES2205560T5 (es) | 1997-09-29 | 1998-09-29 | Preparaciones estabilizadas para usar en inhaladores de dosis medida |
ES98953220T Expired - Lifetime ES2195408T5 (es) | 1997-09-29 | 1998-09-29 | Procedimiento de formación de polvo que comprende micropartículas perforadas. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES98954933T Expired - Lifetime ES2195415T3 (es) | 1997-09-29 | 1998-09-29 | Preparaciones estabilizadas para su uso en nebulizadores. |
ES98950826T Expired - Lifetime ES2205560T5 (es) | 1997-09-29 | 1998-09-29 | Preparaciones estabilizadas para usar en inhaladores de dosis medida |
Country Status (28)
Country | Link |
---|---|
EP (4) | EP1019020A1 (es) |
JP (9) | JP2003525842A (es) |
KR (4) | KR100572171B1 (es) |
CN (1) | CN1169520C (es) |
AT (3) | ATE238035T1 (es) |
AU (4) | AU757337C (es) |
BG (1) | BG64816B1 (es) |
BR (1) | BR9812693A (es) |
CA (4) | CA2304975C (es) |
CZ (1) | CZ300758B6 (es) |
DE (2) | DE69814428T2 (es) |
DK (2) | DK1019022T4 (es) |
EA (2) | EA003665B1 (es) |
EE (1) | EE04628B1 (es) |
ES (3) | ES2195415T3 (es) |
HK (1) | HK1031680A1 (es) |
HR (1) | HRP20000175B1 (es) |
IL (2) | IL135126A0 (es) |
IS (1) | IS2154B (es) |
ME (1) | MEP4108A (es) |
NO (1) | NO340149B1 (es) |
NZ (1) | NZ503464A (es) |
PL (1) | PL195212B1 (es) |
PT (1) | PT1019022E (es) |
RS (1) | RS50182B (es) |
SK (1) | SK285068B6 (es) |
TR (1) | TR200000819T2 (es) |
WO (3) | WO1999016421A1 (es) |
Families Citing this family (235)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
US6503480B1 (en) | 1997-05-23 | 2003-01-07 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
EP1019020A1 (en) * | 1997-09-29 | 2000-07-19 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
US6946117B1 (en) * | 1997-09-29 | 2005-09-20 | Nektar Therapeutics | Stabilized preparations for use in nebulizers |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
US6433040B1 (en) | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
GB9727102D0 (en) * | 1997-12-22 | 1998-02-25 | Andaris Ltd | Microparticles and their therapeutic use |
WO2000000215A1 (en) * | 1998-06-29 | 2000-01-06 | Inhale Therapeutic Systems, Inc. | Particulate delivery systems and methods of use |
JP2003535017A (ja) * | 1998-06-29 | 2003-11-25 | ネクター セラピューティクス | 微粒子デリバリーシステムおよび使用の方法 |
US6630169B1 (en) | 1999-03-31 | 2003-10-07 | Nektar Therapeutics | Particulate delivery systems and methods of use |
US6223455B1 (en) * | 1999-05-03 | 2001-05-01 | Acusphere, Inc. | Spray drying apparatus and methods of use |
CA2371836C (en) * | 1999-05-27 | 2006-01-31 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US6630121B1 (en) | 1999-06-09 | 2003-10-07 | The Regents Of The University Of Colorado | Supercritical fluid-assisted nebulization and bubble drying |
US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
US6586008B1 (en) * | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
CA2382821A1 (en) * | 1999-08-25 | 2001-03-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
US6669960B2 (en) | 1999-12-21 | 2003-12-30 | Rxkinetix, Inc. | Particulate drug-containing products and method of manufacture |
US6761909B1 (en) | 1999-12-21 | 2004-07-13 | Rxkinetix, Inc. | Particulate insulin-containing products and method of manufacture |
GB0003935D0 (en) * | 2000-02-08 | 2000-04-12 | King S College London | Formulation for dry powder inhaler |
US6764725B2 (en) | 2000-02-08 | 2004-07-20 | 3M Innovative Properties Company | Ink fixing materials and methods of fixing ink |
ATE304453T1 (de) | 2000-02-08 | 2005-09-15 | 3M Innovative Properties Co | Verbesserte verfahren für kalten bildtransfer |
US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
US7442388B2 (en) | 2000-05-10 | 2008-10-28 | Weers Jeffry G | Phospholipid-based powders for drug delivery |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
WO2001087277A2 (en) * | 2000-05-15 | 2001-11-22 | Vectura Limited | Method of manufacturing particles |
NZ523693A (en) * | 2000-07-10 | 2004-08-27 | Chiron Corp | Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
US7141236B2 (en) | 2000-07-28 | 2006-11-28 | Nektar Therapeutics | Methods and compositions for delivering macromolecules to or via the respiratory tract |
DE10064219B9 (de) * | 2000-12-22 | 2009-02-12 | Nasalis Pain Relief International Gmbh | Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung |
US20030072717A1 (en) | 2001-02-23 | 2003-04-17 | Vapotronics, Inc. | Inhalation device having an optimized air flow path |
GB0106403D0 (en) * | 2001-03-15 | 2001-05-02 | Pharmaceutical Profiles | Labelling of dry powder formulations for inhalation |
GB0107106D0 (en) * | 2001-03-21 | 2001-05-09 | Boehringer Ingelheim Pharma | Powder inhaler formulations |
WO2002087542A1 (en) * | 2001-04-26 | 2002-11-07 | Inhale Therapeutic Systems, Inc. | Novel methods and compositions for delivering macromolecules to or via the respiratory tract |
US7905230B2 (en) | 2001-05-09 | 2011-03-15 | Novartis Ag | Metered dose inhaler with lockout |
CN1236831C (zh) * | 2001-05-21 | 2006-01-18 | 茵捷特数码浮质有限公司 | 用于经肺部途径递送蛋白质的组合物 |
US6737043B2 (en) | 2001-05-24 | 2004-05-18 | Alexza Molecula Delivery Corporation | Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
WO2002094242A1 (en) | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of rizatriptan or zolmitriptan through an inhalation route |
EP1392262A1 (en) | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
US7078016B2 (en) | 2001-11-21 | 2006-07-18 | Alexza Pharmaceuticals, Inc. | Delivery of caffeine through an inhalation route |
US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
US6805853B2 (en) | 2001-11-09 | 2004-10-19 | Alexza Molecular Delivery Corporation | Delivery of diazepam through an inhalation route |
TW553752B (en) | 2001-06-20 | 2003-09-21 | Inhale Therapeutic Syst | Powder aerosolization apparatus and method |
EP1487417A4 (en) * | 2001-09-17 | 2010-03-17 | Glaxo Group Ltd | DRY POWDER DRUG FORMULATIONS |
DE60227691D1 (de) | 2001-11-01 | 2008-08-28 | Nektar Therapeutics | Sprühtrocknungsverfahren |
CA2468958C (en) | 2001-12-19 | 2012-07-03 | Nektar Therapeutics | Pulmonary delivery of aminoglycosides |
AU2002351271A1 (en) | 2001-12-21 | 2003-07-24 | Nektar Therapeutics | Capsule package with moisture barrier |
CA2477592A1 (en) * | 2002-03-18 | 2003-09-25 | Yamanouchi Pharmaceutical Co., Ltd. | Powdery medicinal compositions for inhalation and process for producing the same |
US7008644B2 (en) | 2002-03-20 | 2006-03-07 | Advanced Inhalation Research, Inc. | Method and apparatus for producing dry particles |
US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
US6941980B2 (en) | 2002-06-27 | 2005-09-13 | Nektar Therapeutics | Apparatus and method for filling a receptacle with powder |
AR040682A1 (es) | 2002-07-25 | 2005-04-13 | Pharmacia Corp | Forma de dosificacion una vez al dia de pramipexol |
EP1556018A1 (en) * | 2002-09-30 | 2005-07-27 | Acusphere, Inc. | Sustained release porous microparticles for inhalation |
US7516741B2 (en) | 2002-12-06 | 2009-04-14 | Novartis Ag | Aerosolization apparatus with feedback mechanism |
JP2006511617A (ja) * | 2002-12-13 | 2006-04-06 | アダーギット | 製薬用多孔質粒子 |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
EP1589947B2 (en) * | 2002-12-31 | 2019-01-30 | Novartis AG | Pharmaceutical formulation with an insoluble active agent for pulmonary administration |
US7669596B2 (en) | 2002-12-31 | 2010-03-02 | Novartis Pharma Ag | Aerosolization apparatus with rotating capsule |
WO2004073729A1 (ja) | 2003-02-21 | 2004-09-02 | Translational Research Ltd. | 薬物の経鼻投与用組成物 |
JP4607010B2 (ja) | 2003-02-28 | 2011-01-05 | 中外製薬株式会社 | タンパク質含有安定化製剤 |
CA2519287A1 (en) | 2003-03-27 | 2004-10-14 | Bioactis Limited | Powder medicine applicator for nasal cavity |
WO2004091707A2 (en) | 2003-04-09 | 2004-10-28 | Nektar Therapeutics | Aerosolization apparatus with capsule puncture alignment guide |
US7559325B2 (en) | 2003-04-09 | 2009-07-14 | Novartis Pharma Ag | Aerosolization apparatus with air inlet shield |
US8869794B1 (en) | 2003-04-09 | 2014-10-28 | Novartis Pharma Ag | Aerosolization apparatus with capsule puncturing member |
EP1625334B9 (en) | 2003-05-21 | 2012-07-25 | Alexza Pharmaceuticals, Inc. | Percussively ignited self-contained heating unit |
EP1635786A2 (en) | 2003-05-28 | 2006-03-22 | Nektar Therapeutics | Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agent microparticle with a partial or complete amino acid and/or phospholipid coat |
JP2007533634A (ja) * | 2003-09-30 | 2007-11-22 | アキュスフィア, インコーポレイテッド | 注射、経口、または局所用の徐放性医薬製剤 |
US7621299B2 (en) | 2003-10-03 | 2009-11-24 | Cabot Corporation | Method and apparatus for filling a vessel with particulate matter |
JP2007509989A (ja) * | 2003-10-31 | 2007-04-19 | ポイント バイオメディカル コーポレイション | 超音波造影剤として有用な再構成可能なミクロスフィア組成物 |
EP1701714A2 (en) | 2004-01-07 | 2006-09-20 | Nektar Therapeutics | Improved sustained release compositions for pulmonary administration of insulin |
US20080026066A1 (en) * | 2004-04-13 | 2008-01-31 | Cambridge Biostability Limited | Liquids Containing Suspended Glass Particles |
ITMI20040795A1 (it) | 2004-04-23 | 2004-07-23 | Eratech S R L | Composizione farmaceutica solida secca suo processo di preparazione e sospensione acquosa stabile ottenuta dalla stessa |
US8012457B2 (en) | 2004-06-04 | 2011-09-06 | Acusphere, Inc. | Ultrasound contrast agent dosage formulation |
US8513204B2 (en) | 2004-06-21 | 2013-08-20 | Novartis Ag | Compositions comprising amphotericin B, mehods and systems |
CA2567785A1 (en) | 2004-06-21 | 2006-01-05 | Nektar Therapeutics | Composition comprising amphotericin b methods and systems |
US8673360B2 (en) | 2004-08-10 | 2014-03-18 | Shin Nippon Biomedical Laboratories, Ltd. | Compositions that enable rapid-acting and highly absorptive intranasal administration |
CN101849921A (zh) | 2004-08-13 | 2010-10-06 | 贝林格尔·英格海姆国际有限公司 | 包含普拉克索或其可药用盐的延长释放片剂 |
JP4971159B2 (ja) | 2004-08-13 | 2012-07-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | プラミペキソール又はその薬学的に許容しうる塩を含有する徐放性ペレット製剤、その製法及び使用 |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
AU2006226887A1 (en) * | 2005-03-23 | 2006-09-28 | Elan Pharma International Limited | Nanoparticulate corticosteroid and antihistamine formulations |
PA8672101A1 (es) | 2005-04-29 | 2006-12-07 | Centocor Inc | Anticuerpos anti-il-6, composiciones, métodos y usos |
WO2006124446A2 (en) * | 2005-05-12 | 2006-11-23 | Nektar Therapeutics | Sustained release microparticles for pulmonary delivery |
CA2607148C (en) | 2005-05-18 | 2014-12-23 | Nektar Therapeutics | Valves, devices, and methods for endobronchial therapy |
TW200716174A (en) | 2005-05-19 | 2007-05-01 | Centocor Inc | Anti-MCP-1 antibodies, compositions, methods and uses |
EP3501537A1 (en) | 2005-06-30 | 2019-06-26 | Janssen Biotech, Inc. | Anti-il23 antibodies, compositions, methods and uses |
ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
JP5113328B2 (ja) * | 2005-11-07 | 2013-01-09 | 田辺三菱製薬株式会社 | エマルション並びにそれを用いた目的物質粒子の製造方法及び医薬品 |
EP1968644B1 (en) | 2005-12-16 | 2012-06-27 | Nektar Therapeutics | Polymer conjugates of glp-1 |
PL1971366T3 (pl) | 2005-12-29 | 2015-01-30 | Janssen Biotech Inc | Ludzkie przeciwciała skierowane przeciw IL-23, kompozycje, sposoby i zastosowanie |
EP1976486A1 (en) * | 2006-01-27 | 2008-10-08 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | A method of producing porous microparticles |
KR101106510B1 (ko) | 2006-05-30 | 2012-01-20 | 인타르시아 세라퓨틱스 인코포레이티드 | 투피스, 내부채널 삼투압 전달 시스템 유동 조절기 |
DK2049081T3 (da) | 2006-08-09 | 2013-02-25 | Intarcia Therapeutics Inc | Osmotiske leveringssystemer og stempelarrangementer |
CN101668544B (zh) | 2006-12-26 | 2013-04-24 | 株式会社新日本科学 | 经鼻投用制剂 |
US20080216828A1 (en) | 2007-03-09 | 2008-09-11 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
ES2402172T3 (es) | 2007-04-23 | 2013-04-29 | Intarcia Therapeutics, Inc | Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos |
WO2009023803A2 (en) * | 2007-08-15 | 2009-02-19 | Abbott Respiratory Llc | Modulated release formulation for the delivery of one or more medicaments |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
WO2009120619A2 (en) * | 2008-03-24 | 2009-10-01 | Novartis Ag | Nuclease compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions |
PL220269B1 (pl) | 2008-04-21 | 2015-09-30 | Przedsiębiorstwo Produkcji Farmaceutycznej Hasco Lek Spółka Akcyjna | Kompozytowy nośnik leków proszkowych, sposób wytwarzania nośnika leków oraz urządzenie do wytwarzania cząstek nośnika kompozytowego |
MX2010012452A (es) | 2008-05-15 | 2011-03-15 | Novartis Ag Star | Suministro pulmonar de una fluoro-quinolona. |
MX2011003117A (es) | 2008-09-19 | 2011-04-21 | Nektar Therapeutics | Conjugados polimericos de peptidos terapeuticos. |
RS55218B1 (sr) | 2008-10-31 | 2017-02-28 | Janssen Biotech Inc | Kompozicije fibronektin tip iii skalno baziranih domena, metode i upotrebe |
MX2011004730A (es) * | 2008-11-04 | 2011-05-30 | Cipla Ltd | Composicion farmaceutica en aerosol. |
US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
JP5873335B2 (ja) | 2009-02-12 | 2016-03-01 | ヤンセン バイオテツク,インコーポレーテツド | フィブロネクチンiii型ドメインに基づくスカフォールド組成物、方法及び使用 |
EP2221048A1 (en) | 2009-02-18 | 2010-08-25 | Siegfried Generics International AG | Pharmaceutical composition for inhalation |
CA2835771C (en) | 2009-03-18 | 2017-01-24 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
EP3184099A1 (en) | 2009-03-26 | 2017-06-28 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
GB0908129D0 (en) * | 2009-05-12 | 2009-06-24 | Innovata Ltd | Composition |
KR20100123240A (ko) * | 2009-05-15 | 2010-11-24 | 포항공과대학교 산학협력단 | 호흡기 염증성 질환의 치료 또는 예방을 위한 호흡기내 투여용 약학 제제 및 상기 질환의 치료 또는 예방 방법 |
EP2429495A4 (en) | 2009-05-15 | 2014-01-22 | Shin Nippon Biomedical Lab Ltd | INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PHARMACOKINETICS |
US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
TWI695723B (zh) * | 2009-05-29 | 2020-06-11 | 美商沛爾醫療股份有限公司 | 用於經由呼吸道輸送活性劑的組成物以及相關方法與系統 |
WO2011013003A2 (en) | 2009-07-31 | 2011-02-03 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal granisetron and nasal applicator |
CN107638562B (zh) | 2009-09-28 | 2022-12-02 | 精达制药公司 | 基本稳态药物递送的快速建立和/或终止 |
CN102811715A (zh) * | 2009-12-08 | 2012-12-05 | 悉尼大学 | 可吸入制剂 |
US9061352B2 (en) | 2010-08-30 | 2015-06-23 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
WO2012030647A1 (en) | 2010-08-30 | 2012-03-08 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
WO2012050945A1 (en) | 2010-09-29 | 2012-04-19 | Pulmatrix, Inc. | Cationic dry powders |
WO2012044736A1 (en) | 2010-09-29 | 2012-04-05 | Pulmatrix, Inc. | Monovalent metal cation dry powders for inhalation |
JP2013540827A (ja) * | 2010-10-29 | 2013-11-07 | ウエスタン ユニバーシティ オブ ヘルス サイエンシズ | 三種混合製剤 |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
AU2012222074A1 (en) * | 2011-02-25 | 2013-09-12 | National Institutes Of Health | Chalcone derivatives as Nrf2 activators |
GB201108039D0 (en) | 2011-05-13 | 2011-06-29 | Mexichem Amanco Holding Sa | Compositions |
AU2011368334A1 (en) * | 2011-05-17 | 2013-11-21 | Pearl Therapeutics, Inc. | Compositions, methods & systems for respiratory delivery of two or more active agents |
GB201117619D0 (en) | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
GB201117621D0 (en) * | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
EP2601941A1 (en) | 2011-12-06 | 2013-06-12 | Ludwig-Maximilians-Universität München | Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents |
US9763965B2 (en) | 2012-04-13 | 2017-09-19 | Glaxosmithkline Intellectual Property Development Limited | Aggregate particles |
JP6499077B2 (ja) | 2012-10-25 | 2019-04-10 | ザ ジェネラル ホスピタル コーポレイション | アルツハイマー病と関連疾患の治療のための併用療法 |
US20140275517A1 (en) | 2013-03-15 | 2014-09-18 | Pearl Therapeutics, Inc. | Methods and systems for conditioning of particulate crystalline materials |
GB201306984D0 (en) * | 2013-04-17 | 2013-05-29 | Mexichem Amanco Holding Sa | Composition |
EP2991634A1 (en) | 2013-04-30 | 2016-03-09 | Otitopic Inc. | Dry powder formulations and methods of use |
KR101543507B1 (ko) * | 2013-05-15 | 2015-08-11 | 씨제이헬스케어 주식회사 | 연속 공정의 미립구의 제조 방법 및 이로부터 제조된 미립구 |
US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
CA2913235C (en) * | 2013-05-23 | 2021-07-13 | Aztherapies, Inc. | Methods for delivering cromolyn |
WO2014207213A1 (en) | 2013-06-28 | 2014-12-31 | Medizinische Universität Innsbruck | Novel inhibitors of protein kinase c epsilon signaling |
CN110305095A (zh) * | 2013-10-22 | 2019-10-08 | 综合医院公司 | 色甘酸衍生物以及成像和治疗的相关方法 |
ES2792682T3 (es) | 2014-02-10 | 2020-11-11 | Respivant Sciences Gmbh | Métodos para el tratamiento de enfermedades pulmonares con estabilizadores de mastocitos |
PT3104853T (pt) | 2014-02-10 | 2020-01-14 | Respivant Sciences Gmbh | Tratamento com estabilizadores de mastócitos para distúrbios sistémicos |
DK3107548T3 (da) | 2014-02-20 | 2022-07-18 | Otitopic Inc | Tørpulverformuleringer til inhalation |
EP2947460A1 (en) | 2014-05-22 | 2015-11-25 | Medizinische Universität Wien | Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists |
ES2942297T3 (es) | 2014-07-31 | 2023-05-31 | Vectura Inc | Formulaciones de polvo seco para inhalación |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
CA2965759C (en) | 2014-10-31 | 2023-12-12 | Glaxosmithkline Intellectual Property Development Limited | Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials |
JP6395216B2 (ja) * | 2014-11-13 | 2018-09-26 | 国立大学法人大阪大学 | 液体に含まれる超微細バブルの測定方法及びその測定装置 |
WO2016118625A1 (en) | 2015-01-20 | 2016-07-28 | Incarda Therapeutics, Inc. | Unit aerosol doses for anticoagulation |
WO2016135137A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135138A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135139A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135140A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016170102A1 (en) | 2015-04-22 | 2016-10-27 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer |
US10925639B2 (en) | 2015-06-03 | 2021-02-23 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
EP3331522A1 (en) | 2015-08-07 | 2018-06-13 | Patara Pharma LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
EP3701940A1 (en) | 2015-12-04 | 2020-09-02 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition |
RS62412B1 (sr) | 2015-12-09 | 2021-10-29 | Univ Wien Med | Jedinjenja platine funkcionalizovana sa monomaleimidom za terapiju raka |
AU2017207867A1 (en) | 2016-01-15 | 2018-08-09 | Universität Hamburg | Flavonoide-type compounds bearing an O-rhamnosyl residue |
KR20180102201A (ko) | 2016-02-01 | 2018-09-14 | 인카다 테라퓨틱스, 인크. | 심방 세동을 포함한 심장 부정맥을 관리하기 위한 전자 모니터링과 흡입 약리 치료의 조합 |
MX2018009870A (es) | 2016-02-15 | 2018-11-29 | Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh | Inhibidores de taf1 para la terapia del cancer. |
US10765724B2 (en) | 2016-03-29 | 2020-09-08 | Janssen Biotech, Inc. | Method of treating psoriasis with increased interval dosing of anti-IL12/23 antibody |
GB2555264A (en) | 2016-04-15 | 2018-04-25 | Univ Oxford Innovation Ltd | Adenosine receptor modulators for the treatment of circadian rhythm disorders |
BR112018073511A2 (pt) | 2016-05-16 | 2019-03-26 | Intarcia Therapeutics, Inc. | polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
WO2018014039A1 (en) | 2016-07-15 | 2018-01-18 | Poseida Therapeutics, Inc. | Chimeric antigen receptors (cars) specific for muc1 and methods for their use |
US20190177421A1 (en) | 2016-07-15 | 2019-06-13 | Poseida Therapeutics, Inc. | Chimeric antigen receptors and methods for use |
CA3035528A1 (en) | 2016-08-31 | 2018-03-08 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
JP2019524865A (ja) | 2016-08-31 | 2019-09-05 | ザ ジェネラル ホスピタル コーポレイション | 神経変性疾患と関連する神経炎症におけるマクロファージ/ミクログリア |
ES2957459T3 (es) | 2016-09-19 | 2024-01-19 | Mexichem Fluor Sa De Cv | Composición farmacéutica que comprende glicopirrolato |
AU2017328910B2 (en) | 2016-09-19 | 2020-04-09 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
WO2018051131A1 (en) | 2016-09-19 | 2018-03-22 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
CA3037080C (en) | 2016-09-19 | 2021-05-18 | Mexichem Fluor S.A. De C.V. | Stable pharmaceutical compositions comprising indacaterol and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis) |
AU2017336799B2 (en) | 2016-09-30 | 2023-08-31 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-IL23 specific antibody |
CN109803724A (zh) | 2016-10-07 | 2019-05-24 | 瑞思皮万特科学有限责任公司 | 用于治疗肺纤维化的色甘酸组合物 |
US20190262355A1 (en) | 2016-11-14 | 2019-08-29 | Cemm-Forschungszentrum Für Molekulare Medizin Gmbh | Combination of a brd4 inhibitor and an antifolate for the therapy of cancer |
MX2019005661A (es) | 2016-11-16 | 2019-10-07 | Janssen Biotech Inc | Método para tratar la psoriasis con el anticuerpo específico anti-il23. |
MX2019008006A (es) | 2017-01-03 | 2019-08-29 | Intarcia Therapeutics Inc | Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco. |
WO2018209107A1 (en) | 2017-05-10 | 2018-11-15 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
CA3062570A1 (en) | 2017-05-22 | 2018-11-29 | Insmed Incorporated | Lipo-glycopeptide cleavable derivatives and uses thereof |
AU2017423862A1 (en) | 2017-07-20 | 2020-02-06 | Aztherapies, Inc. | Powdered formulations of cromolyn sodium and ibuprofen |
JP2020532987A (ja) | 2017-09-08 | 2020-11-19 | ポセイダ セラピューティクス,インコーポレイティド | キメラリガンド受容体(clr)介在性の条件遺伝子発現のための組成物および方法 |
TW201922780A (zh) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗il12/il23抗體治療狼瘡之安全且有效之方法 |
US11744967B2 (en) | 2017-09-26 | 2023-09-05 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal delivery devices |
WO2019110139A1 (en) | 2017-12-05 | 2019-06-13 | Eth Zurich | New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors |
MX2020006689A (es) | 2017-12-20 | 2020-11-06 | Poseida Therapeutics Inc | Composiciones de vcar y metodos de uso. |
WO2019171252A1 (en) | 2018-03-05 | 2019-09-12 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
US20210107993A1 (en) | 2018-03-07 | 2021-04-15 | Poseida Therapeutics, Inc. | Cartyrin compositions and methods for use |
WO2019183470A2 (en) | 2018-03-22 | 2019-09-26 | Incarda Therapeutics, Inc. | A novel method to slow ventricular rate |
US20210163406A1 (en) | 2018-04-06 | 2021-06-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs |
KR20200143413A (ko) | 2018-04-06 | 2020-12-23 | 지렌틴 아게 | 다한증 치료용 부메타니드 유도체 |
JP2021523138A (ja) | 2018-05-11 | 2021-09-02 | ヤンセン バイオテツク,インコーポレーテツド | Il−23抗体を使用してうつを治療する方法 |
US10414721B1 (en) | 2018-06-04 | 2019-09-17 | University Of Bern | Inhibitor of endocannabinoid cellular reuptake |
JP2021529771A (ja) | 2018-07-02 | 2021-11-04 | ザ ジェネラル ホスピタル コーポレイション | クロモリンナトリウムおよびα−ラクトースの粉末製剤 |
JP2021530697A (ja) | 2018-07-18 | 2021-11-11 | ヤンセン バイオテツク,インコーポレーテツド | 抗il23特異的抗体で治療した後の持続応答予測因子 |
CA3113837C (en) | 2018-09-24 | 2022-07-12 | Janssen Biotech, Inc. | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
EP3883607A4 (en) | 2018-11-20 | 2022-08-17 | Janssen Biotech, Inc. | SAFE AND EFFECTIVE PROCESS FOR TREATING PSORIASIS WITH A SPECIFIC ANTI-IL-23 ANTIBODY |
AU2019407650B2 (en) | 2018-12-17 | 2022-10-27 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer |
MA54562A (fr) | 2018-12-18 | 2021-10-27 | Janssen Biotech Inc | Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23 |
MX2021008149A (es) | 2019-01-03 | 2021-11-12 | Aqua Yield Operations LLC | Dendrimeros de pamam para el suministro de fertilizantes. |
KR20210141990A (ko) | 2019-03-14 | 2021-11-23 | 얀센 바이오테크 인코포레이티드 | 항-il12/il23 항체 조성물을 생성하기 위한 제조 방법 |
MA55383A (fr) | 2019-03-18 | 2022-01-26 | Janssen Biotech Inc | Méthode de traitement du psoriasis chez des sujets pédiatriques avec un anticorps anti-il12/il23 |
US11932585B2 (en) * | 2019-04-12 | 2024-03-19 | Aqua Yield Operations LLC | Blended nanoparticle fertilizer delivery |
CN110051868A (zh) * | 2019-04-15 | 2019-07-26 | 宝盈联华(厦门)生物科技有限公司 | 一种带有硅碳岩、礌石粉的橱柜灭菌器 |
JP7404671B2 (ja) * | 2019-06-25 | 2023-12-26 | 株式会社リコー | 多孔質微粒子及びその製造方法、並びに医薬組成物 |
US11007185B2 (en) | 2019-08-01 | 2021-05-18 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
WO2021064141A1 (en) | 2019-10-02 | 2021-04-08 | Tolremo Therapeutics Ag | Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b |
AU2020360709B2 (en) | 2019-10-02 | 2024-02-15 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer |
WO2021074414A1 (en) | 2019-10-16 | 2021-04-22 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof |
WO2021074418A1 (en) | 2019-10-16 | 2021-04-22 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof |
MX2022012956A (es) | 2020-04-14 | 2023-03-27 | Poseida Therapeutics Inc | Composiciones y métodos para su uso en el tratamiento del cáncer. |
US20230158125A1 (en) | 2020-04-20 | 2023-05-25 | Sorrento Therapeutics, Inc. | Pulmonary Administration of ACE2 Polypeptides |
WO2021214588A1 (en) | 2020-04-21 | 2021-10-28 | Janssen Biotech, Inc. | Anti-tnf alpha agent for treating coronavirus infections |
WO2021214587A1 (en) | 2020-04-21 | 2021-10-28 | Janssen Biotech, Inc. | Anti-tnf alpha agent for treating viral infections |
US20230226057A1 (en) | 2020-06-25 | 2023-07-20 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease |
EP3939578A1 (en) | 2020-07-13 | 2022-01-19 | Novaremed Ltd. | Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease |
CN111700883B (zh) * | 2020-07-23 | 2021-04-06 | 深圳大佛药业股份有限公司 | 一种硫酸沙丁胺醇缓释型吸入制剂及其生产工艺 |
EP3964497A1 (en) | 2020-09-04 | 2022-03-09 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain |
US20230270669A1 (en) | 2020-09-04 | 2023-08-31 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
AU2021359129A1 (en) | 2020-10-16 | 2023-06-01 | Proxygen Gmbh | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof |
CN112495316B (zh) * | 2020-10-20 | 2021-11-19 | 大连理工大学 | 一种基于亚稳态乳液制备微纳米凝胶微球的方法 |
WO2022122012A1 (zh) * | 2020-12-11 | 2022-06-16 | 江苏恒瑞医药股份有限公司 | 用于肺部递送的药物组合物 |
CA3212729A1 (en) | 2021-03-12 | 2022-09-15 | Janssen Biotech, Inc. | Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody |
WO2022189662A1 (en) | 2021-03-12 | 2022-09-15 | Alvarius Pharmaceuticals Ltd. | Compositions and methods for treating addictions comprising 5-meo-dmt |
JP2024510588A (ja) | 2021-03-12 | 2024-03-08 | ヤンセン バイオテツク,インコーポレーテツド | 抗il23特異的抗体による、tnf療法に対する不十分な応答を有する乾癬性関節炎患者を治療する方法 |
WO2022214606A1 (en) | 2021-04-07 | 2022-10-13 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer |
IL309987A (en) | 2021-07-09 | 2024-03-01 | Janssen Biotech Inc | Production methods for the production of anti-IL12/IL23 antibody compositions |
IL312401A (en) | 2021-10-29 | 2024-06-01 | Janssen Biotech Inc | Methods for treating Crohn's disease with a specific anti-IL23 antibody |
CA3238377A1 (en) | 2021-11-15 | 2023-05-19 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
CA3239216A1 (en) | 2021-11-23 | 2023-06-01 | Janssen Biotech, Inc. | Method of treating ulcerative colitis with anti-il23 specific antibody |
US20230312703A1 (en) | 2022-03-30 | 2023-10-05 | Janssen Biotech, Inc. | Method of Treating Psoriasis with IL-23 Specific Antibody |
WO2023203174A1 (en) | 2022-04-20 | 2023-10-26 | Proxygen Gmbh | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof |
WO2023223265A1 (en) | 2022-05-18 | 2023-11-23 | Janssen Biotech, Inc. | Method for evaluating and treating psoriatic arthritis with il23 antibody |
CN115144310A (zh) * | 2022-07-01 | 2022-10-04 | 重庆交通大学 | 一种旋桨式絮凝沉降试验装置及方法 |
US20240199734A1 (en) | 2022-11-22 | 2024-06-20 | Janssen Biotech, Inc. | Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1410588A (en) † | 1971-08-10 | 1975-10-22 | Fisons Ltd | Composition |
JPS5134879A (en) * | 1974-09-19 | 1976-03-24 | Eisai Co Ltd | Bishochukuryushinoseizoho |
US4147766A (en) † | 1976-06-09 | 1979-04-03 | Armour Pharmaceutical Company | Macrospherical particles of anti-perspirants |
EP0072046B1 (en) † | 1981-07-24 | 1986-01-15 | FISONS plc | Inhalation drugs, methods for their production and pharmaceutical formulations containing them |
WO1989005632A1 (en) * | 1983-11-14 | 1989-06-29 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
GB8502892D0 (en) * | 1985-02-05 | 1985-03-06 | Sterwin Ag | Aerosol composition |
WO1986006959A1 (en) * | 1985-05-22 | 1986-12-04 | Liposome Technology, Inc. | Liposome inhalation method and system |
US4950477A (en) † | 1988-08-23 | 1990-08-21 | Memorial Hospital For Cancer And Allied Dieseas | Method of preventing and treating pulmonary infection by fungi using aerosolized polyenes |
GB8828477D0 (en) * | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
WO1990013285A1 (en) * | 1989-05-01 | 1990-11-15 | Enzytech, Inc. | Process for producing small particles of biologically active molecules |
US5733572A (en) * | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5585112A (en) * | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
CA2081474A1 (en) † | 1990-05-08 | 1991-11-09 | Manzer Durrani | Direct spray-dried drug/lipid powder composition |
US5126123A (en) † | 1990-06-28 | 1992-06-30 | Glaxo, Inc. | Aerosol drug formulations |
US5230884A (en) † | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
US5304125A (en) † | 1990-10-05 | 1994-04-19 | The University Of North Carolina | Apparatus for administering solid particulate aerosols to the lungs |
EP0495187B1 (en) * | 1991-01-15 | 1997-01-22 | Hemosphere, Inc. | Protein nanomatrixes and method of production |
US5616311A (en) * | 1991-01-15 | 1997-04-01 | Hemosphere, Inc. | Non-crosslinked protein particles for therapeutic and diagnostic use |
US5182097A (en) † | 1991-02-14 | 1993-01-26 | Virginia Commonwealth University | Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
NZ241954A (en) † | 1991-03-15 | 1994-01-26 | Amgen Inc | Compositions of g-csf for pulmonary administration. |
SE9101090D0 (sv) * | 1991-04-11 | 1991-04-11 | Astra Ab | Process for conditioning of water-soluble substances |
JPH05500229A (ja) * | 1991-04-12 | 1993-01-21 | 東レ株式会社 | 固体ポリペプチド微粒子のエアロゾル製剤とその製造方法 |
PT656207E (pt) * | 1991-06-10 | 2001-11-30 | Schering Corp | Formulacoes de aerossois sem clorofluorocarbonetos |
DK0617610T3 (da) * | 1991-12-18 | 1997-10-06 | Minnesota Mining & Mfg | Suspensionsaerosolformuleringer. |
US5376359A (en) † | 1992-07-07 | 1994-12-27 | Glaxo, Inc. | Method of stabilizing aerosol formulations |
US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
US5354934A (en) † | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
DE4323636A1 (de) * | 1993-07-15 | 1995-01-19 | Hoechst Ag | Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung |
US5798091A (en) † | 1993-07-30 | 1998-08-25 | Alliance Pharmaceutical Corp. | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
DK0711179T3 (da) * | 1993-07-30 | 2005-02-14 | Imcor Pharmaceutical Co | Stabiliserede sammensætninger med mikrobobler til ultralyd |
EP0655237A1 (de) * | 1993-11-27 | 1995-05-31 | Hoechst Aktiengesellschaft | Medizinische Aerosolformulierung |
US5540909A (en) * | 1994-09-28 | 1996-07-30 | Alliance Pharmaceutical Corp. | Harmonic ultrasound imaging with microbubbles |
KR970705979A (ko) * | 1994-09-29 | 1997-11-03 | 디 히스 | 치료용 매개체로서의 분무-건조 미소입자 (Spray-dried microparticles as therapeutic vehicles) |
GB9423419D0 (en) * | 1994-11-19 | 1995-01-11 | Andaris Ltd | Preparation of hollow microcapsules |
US6524557B1 (en) * | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
ATE236617T1 (de) * | 1994-12-22 | 2003-04-15 | Astrazeneca Ab | Aerosol-arzneiformulierungen |
CA2218074C (en) * | 1995-04-14 | 2002-10-08 | Mohammed Eljamal | Powdered pharmaceutical formulations having improved dispersibility |
US5654007A (en) * | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
EP1444991A1 (en) † | 1995-06-07 | 2004-08-11 | Imarx Pharmaceutical Corp. | Novel targeted compositions for diagnostic and therapeutic use |
US6041777A (en) * | 1995-12-01 | 2000-03-28 | Alliance Pharmaceutical Corp. | Methods and apparatus for closed-circuit ventilation therapy |
GB9606677D0 (en) * | 1996-03-29 | 1996-06-05 | Glaxo Wellcome Inc | Process and device |
CA2277801C (en) † | 1997-01-16 | 2002-10-15 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
EP1019020A1 (en) * | 1997-09-29 | 2000-07-19 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
-
1998
- 1998-09-29 EP EP98950824A patent/EP1019020A1/en not_active Withdrawn
- 1998-09-29 DE DE69814428T patent/DE69814428T2/de not_active Expired - Lifetime
- 1998-09-29 CZ CZ20001115A patent/CZ300758B6/cs not_active IP Right Cessation
- 1998-09-29 AU AU10644/99A patent/AU757337C/en not_active Expired
- 1998-09-29 SK SK449-2000A patent/SK285068B6/sk not_active IP Right Cessation
- 1998-09-29 ES ES98954933T patent/ES2195415T3/es not_active Expired - Lifetime
- 1998-09-29 PT PT98953220T patent/PT1019022E/pt unknown
- 1998-09-29 KR KR1020007003416A patent/KR100572171B1/ko not_active IP Right Cessation
- 1998-09-29 JP JP2000513560A patent/JP2003525842A/ja not_active Withdrawn
- 1998-09-29 ES ES98950826T patent/ES2205560T5/es not_active Expired - Lifetime
- 1998-09-29 AT AT98953220T patent/ATE238035T1/de active
- 1998-09-29 BR BR9812693-8A patent/BR9812693A/pt not_active Application Discontinuation
- 1998-09-29 DE DE69813853T patent/DE69813853T3/de not_active Expired - Lifetime
- 1998-09-29 CN CNB98809603XA patent/CN1169520C/zh not_active Expired - Lifetime
- 1998-09-29 TR TR2000/00819T patent/TR200000819T2/xx unknown
- 1998-09-29 EA EA200200036A patent/EA003665B1/ru not_active IP Right Cessation
- 1998-09-29 JP JP2000513559A patent/JP4526702B2/ja not_active Expired - Fee Related
- 1998-09-29 DK DK98953220.5T patent/DK1019022T4/da active
- 1998-09-29 AT AT98950826T patent/ATE248583T1/de not_active IP Right Cessation
- 1998-09-29 ME MEP-41/08A patent/MEP4108A/xx unknown
- 1998-09-29 PL PL98339732A patent/PL195212B1/pl unknown
- 1998-09-29 AT AT98954933T patent/ATE239447T1/de not_active IP Right Cessation
- 1998-09-29 CA CA002304975A patent/CA2304975C/en not_active Expired - Lifetime
- 1998-09-29 WO PCT/US1998/020613 patent/WO1999016421A1/en active IP Right Grant
- 1998-09-29 AU AU96770/98A patent/AU756693B2/en not_active Ceased
- 1998-09-29 ES ES98953220T patent/ES2195408T5/es not_active Expired - Lifetime
- 1998-09-29 EP EP98954933A patent/EP1019023B1/en not_active Expired - Lifetime
- 1998-09-29 DK DK98950826.2T patent/DK1019021T4/da active
- 1998-09-29 EP EP98950826A patent/EP1019021B2/en not_active Expired - Lifetime
- 1998-09-29 KR KR1020007003401A patent/KR100575070B1/ko not_active IP Right Cessation
- 1998-09-29 WO PCT/US1998/020615 patent/WO1999016422A1/en active IP Right Grant
- 1998-09-29 CA CA002304820A patent/CA2304820C/en not_active Expired - Fee Related
- 1998-09-29 EE EEP200000194A patent/EE04628B1/xx unknown
- 1998-09-29 JP JP2000513558A patent/JP2001517692A/ja active Pending
- 1998-09-29 AU AU96772/98A patent/AU757153B2/en not_active Expired
- 1998-09-29 CA CA002304973A patent/CA2304973C/en not_active Expired - Fee Related
- 1998-09-29 WO PCT/US1998/020602 patent/WO1999016419A1/en active Application Filing
- 1998-09-29 KR KR1020007003368A patent/KR100599634B1/ko not_active IP Right Cessation
- 1998-09-29 EA EA200000375A patent/EA002562B1/ru not_active IP Right Cessation
- 1998-09-29 AU AU11857/99A patent/AU750567B2/en not_active Ceased
- 1998-09-29 EP EP98953220A patent/EP1019022B2/en not_active Expired - Lifetime
- 1998-09-29 IL IL13512698A patent/IL135126A0/xx active IP Right Grant
- 1998-09-29 KR KR1020007003367A patent/KR100589926B1/ko not_active IP Right Cessation
- 1998-09-29 JP JP2000513557A patent/JP5372306B2/ja not_active Expired - Lifetime
- 1998-09-29 NZ NZ503464A patent/NZ503464A/en not_active IP Right Cessation
- 1998-09-29 CA CA002304819A patent/CA2304819C/en not_active Expired - Lifetime
- 1998-09-29 RS YUP-183/00A patent/RS50182B/sr unknown
-
2000
- 2000-03-16 IL IL135126A patent/IL135126A/en not_active IP Right Cessation
- 2000-03-17 BG BG104253A patent/BG64816B1/bg unknown
- 2000-03-24 IS IS5415A patent/IS2154B/is unknown
- 2000-03-28 HR HR20000175A patent/HRP20000175B1/xx not_active IP Right Cessation
- 2000-03-28 NO NO20001618A patent/NO340149B1/no not_active IP Right Cessation
-
2001
- 2001-01-19 HK HK01100524A patent/HK1031680A1/xx not_active IP Right Cessation
-
2009
- 2009-12-01 JP JP2009274003A patent/JP2010047615A/ja not_active Withdrawn
-
2011
- 2011-03-16 JP JP2011058608A patent/JP5739197B2/ja not_active Expired - Lifetime
-
2013
- 2013-07-08 JP JP2013142326A patent/JP6100114B2/ja not_active Expired - Lifetime
- 2013-07-11 JP JP2013145351A patent/JP2013216688A/ja not_active Withdrawn
-
2014
- 2014-06-24 JP JP2014128936A patent/JP6078498B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2195408T3 (es) | Microparticulas perforadas y procedimientos de uso. | |
PT904056E (pt) | Processo e dispositivo para inalacao de medicamentos particulados | |
ES2116353T3 (es) | Polvos para inhalacion y procedimiento para su fabricacion. | |
DE69816054D1 (de) | Einmalinhalator | |
MXPA02008403A (es) | Mejoras en o relacionadas con el suministro de farmacos por via oral. | |
GR3031504T3 (en) | Use of liquid fluorocarbons to facilitate pulmonary drug delivery | |
DE60008425D1 (de) | Medikamentenabgabevorrichtung mit einer feuchtigkeitsbeständigen beschichtung | |
ATE271852T1 (de) | Verbesserte inhalationspräparate | |
TH33149A (th) | สูตรผสมละอองลอยที่เป็นยา |